BioAtla

Bio Atla

Biotechnology, Torreyana Rd, San Diego, , 92121, California, 11085, United States, 51-200 Employees

bioatla.com

  • facebook
  • LinkedIn

phone no Phone Number: 85********

Who is BIOATLA

BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of our discovery and evoluti...

Read More

map
  • 11085 Torreyana Rd, San Diego, California, 92121, United States Headquarters: 11085 Torreyana Rd, San Diego, California, 92121, United States
  • 2007 Date Founded: 2007
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836

checked-icon Does something look wrong? Fix it. | View contact records from BIOATLA

BioAtla Org Chart and Mapping

Employees

Susie Melody

Senior Vice President Human Resources

Nidia M

Medical Science Liaison

Jing Wang

Senior Staff Scientist

Lisa Pelton

Director of Accounting & Assistant Controller

Guoxiang Shen

Executive Director, Head of Clinical Pharmacology

Wei Zhou

Director of Cell Line Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding BioAtla

Answer: BioAtla's headquarters are located at Torreyana Rd, San Diego, , 92121, California, 11085, United States

Answer: BioAtla's phone number is 85********

Answer: BioAtla's official website is https://bioatla.com

Answer: BioAtla's revenue is $25 Million to $50 Million

Answer: BioAtla's SIC: 2836

Answer: BioAtla has 51-200 employees

Answer: BioAtla is in Biotechnology

Answer: BioAtla contact info: Phone number: 85******** Website: https://bioatla.com

Answer: BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our Conditionally Active Biologics (CAB) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. This improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. BioAtla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access